Key result
Angiotensin II induces TGF-beta1 mRNA expression in vascular smooth muscle cells via ERK and AP-1 activation, a process attenuated by ERK inhibition or losartan.
The ERK pathway mediates Angiotensin II-induced TGF-beta1 expression in vascular smooth muscle cells, suggesting a mechanism for vascular remodeling in hypertension.
Identifies ERK mediation of Ang II-TGF-β1 signaling in VSMCs; hypothesis-generating for vascular remodeling therapies.
We have previously demonstrated that angiotensin II (Ang II) contributes to the increase in aortic transforming growth factor-beta(1) (TGF-beta(1)) mRNA levels in hypertensive rats. However, the molecular mechanism whereby Ang II promotes TGF-beta(1) expression in vascular smooth muscle cells (VSMCs) is poorly understood. In this study, we examined the role of extracellular signal-regulated kinase (ERK) in Ang II-mediated TGF-beta(1) expression in VSMCs and the role of Ang II in aortic ERK activity of stroke-prone spontaneously hypertensive rats. Treatment of quiescent VSMCs with 100 nmol/L Ang II induced rapid phosphorylation and activation of ERK1 and ERK2 with a peak at 5 minutes followed by an increase in activator protein-1 (AP-1) DNA binding activity, as shown by gel mobility shift assay. An increase in TGF-beta(1) mRNA was shown by Northern blot analysis. Treatment of VSMCs with PD98059, a specific inhibitor of the ERK pathway, attenuated both the activation of AP-1 and the increase in TGF-beta(1) mRNA induced by Ang II. Inhibition of Ang II-induced AP-1 activation with c-fos antisense oligodeoxynucleotide led to a significant reduction of TGF-beta(1) mRNA in VSMCs. Furthermore, in vivo treatment of stroke-prone spontaneously hypertensive rats with losartan, an Ang II type 1 receptor antagonist, decreased aortic ERK activity. Thus, we show that ERK, through AP-1 activation, is involved in Ang II-induced TGF-beta(1) mRNA expression in VSMCs and suggest that ERK may participate in vascular remodeling of hypertension. However, it remains to be determined whether the increase in TGF-beta(1) mRNA leads to the increase in its active protein.
No takes yet. Share an insight, caveat, or question.
Hamaguchi et al. (1999) studied Hypertension. Angiotensin II was evaluated on ERK activation and TGF-beta1 mRNA expression. Angiotensin II induces TGF-beta1 mRNA expression in vascular smooth muscle cells via ERK and AP-1 activation, a process attenuated by ERK inhibition or losartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: